HRA Pharma expands to Spain and launches ellaOne

21 December 2009

HRA Pharma, a privately-held, France-headquartered company that designs products, devices and supporting services in reproductive health and endocrinology, says that it has expanded its commercial operations to a fifth European country, Spain.

Laboratorios HRA Pharma Espana, its newest subsidiary, was established to support the firm's Pharma's new generation emergency contraception, ellaOne (ulipristal acetate), which was launched today on the Spanish market. The new company will handle the marketing, sales and distribution of ellaOne and of Lysodren (mitotane), HRA Pharma's orphan drug for the symptomatic treatment of advanced adrenal cortical carcinoma. Products will be sold throughout the country by its in-house, dedicated sales force.

Ignacio Garcia has joined the company as general manager following a 20-year career at Schering and Bayer Schering Pharma in Spain, where he was most recently head of the Women's Health Business Unit.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK